Immunome, Inc. (NASDAQ:IMNM) Insider Robert Lechleider Acquires 15,805 Shares

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider bought 15,805 shares of Immunome stock in a transaction on Thursday, November 21st. The stock was acquired at an average cost of $9.48 per share, with a total value of $149,831.40. Following the acquisition, the insider now owns 15,805 shares in the company, valued at approximately $149,831.40. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Immunome Stock Up 16.8 %

NASDAQ IMNM opened at $13.47 on Thursday. The company has a 50-day moving average price of $12.41 and a 200-day moving average price of $13.52. Immunome, Inc. has a 52 week low of $6.93 and a 52 week high of $30.96. The firm has a market capitalization of $840.80 million, a P/E ratio of -1.65 and a beta of 1.82.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new position in shares of Immunome during the 2nd quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Immunome during the second quarter valued at $97,000. Arizona State Retirement System grew its holdings in Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the period. AQR Capital Management LLC grew its holdings in Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares during the period. Finally, Sequoia Financial Advisors LLC purchased a new stake in Immunome in the second quarter worth about $206,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IMNM has been the subject of a number of recent analyst reports. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research report on Friday, October 25th. Stephens assumed coverage on shares of Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Piper Sandler lowered their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome currently has a consensus rating of “Buy” and a consensus target price of $28.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.